AAV-mediated gene transfer for cellular and gene therapy of Parkinson's disease
The group develops viral vectors based on adeno-associated virus for regulatable and specific gene expression in neuroprotective and anti-inflammatory therapeutic strategies for Parkinson’s disease.
The vectors are evaluated both directly in vivo (gene therapy) and ex vivo by infection of immature neural cells prior to transplantation (cellular therapy).
Another goal of the group is to develop pathology-inducible reporter vectors allowing to monitor disease progression and therapeutic interventions in vivo.
AAV-mediated gene transfer into human fetal mesencephalon